Detailed Narrative
Q3 FY26 Performance Driven by International Sales and Adjusted Domestic Growth
Alkem Laboratories reported a total revenue of INR 37,368 million for Q3 FY26, marking a 10.7% year-on-year growth. This performance was significantly bolstered by international sales, which surged by 26.6% YoY to INR 12,157 million. While reported India sales grew 5.5% YoY to INR 24,959 million, management clarified that, adjusted for a high base in Q3 FY25, the underlying domestic business demonstrated double-digit growth, with YTD numbers close to 10%.
Strategic Entry into MedTech with Occlutech Acquisition
A key highlight of the quarter was the acquisition of a 55% stake in Occlutech, a MedTech company specializing in cardiology devices. This strategic move positions Alkem in a high-growth sector, with Occlutech targeting INR 1,000 crores in revenue and a 25% EBITDA margin within 3-5 years. The initial investment for this acquisition is INR 1,100 crores, with an additional INR 100-200 crores planned over the next two years to accelerate R&D, particularly for the Left Atrial Appendage occluder.
Robust Chronic Business and Market Outperformance in India
Despite headwinds in the generic business, Alkem's chronic business segment exhibited a very strong growth trajectory, expanding in high teens. The company showcased strong market share gains by outperforming the Indian Pharmaceutical Market (IPM) in six key therapies: anti-infectives (1.4x), vitamins & minerals (2x), pain (1.4x), antidiabetic (1.2x, over 2x excluding GLP-1), respiratory (1.2x), and derma (1.8x). This performance underscores the strength of its prescription business.
EBITDA Margin and Profitability Drivers
The company achieved an EBITDA margin of 22.2%, with EBITDA growing 9% YoY to INR 8,280 million. Net profit for the quarter was INR 6,360 million, a 1.6% YoY increase. R&D expenses accounted for 3.7% of total revenue, amounting to INR 1,390 million. Management expects Occlutech, currently EBITDA positive in CY26, to reach 10% EBITDA by FY27 and 23-24% within three years, further contributing to overall group profitability.
Addressing Debt and Future Growth Opportunities
Alkem plans to refinance Occlutech's existing loan of INR 450-500 crores, aiming to reduce the interest rate from 10% to 5-6% by leveraging its corporate guarantee. This move is expected to improve Occlutech's PAT. The company is also looking forward to the US entry of its Denosumab biosimilar (Xgeva) by the end of 2026 and Europe entry in the next couple of months, alongside the PFO launch in the US by June 2027, which are expected to drive future growth.
Impact of Labour Codes and MIP on Operations
An exceptional item📎 of INR 528 million was recorded in the quarter due to the Government of India's notification regarding Labour Codes. Additionally, the Minimum Import Price (MIP) for PenG derivatives is estimated to have an overall impact of INR 80-100 crores. However, management believes that some of this impact could be mitigated through market pricing adjustments, particularly within its trade generic business portfolio.